Marshall Wace’s Clearside Biomedical CLSD Stock Holding History

Marshall Wace’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,141	Closed	-$80.8K	–	2559
2024 Q2	$80.8K	Sell	4,141 -423	-9%	-$8.17K	﹤0.01%	2408
2024 Q1	$105K	Buy	+4,564	New	+$98.4K	﹤0.01%	2306
2022 Q4	–	Sell	-10,178	Closed	-$173K	–	2982
2022 Q3	$173K	Sell	10,178 -4,343	-30%	-$95.1K	﹤0.01%	3117
2022 Q2	$321K	Sell	14,521 -12,948	-47%	-$314K	﹤0.01%	2999
2022 Q1	$943K	Buy	+27,469	New	+$822K	﹤0.01%	2484
2021 Q4	–	Sell	-3,565	Closed	-$321K	–	3909
2021 Q3	$321K	Sell	3,565 -11,798	-77%	-$1.04M	﹤0.01%	2618
2021 Q2	$1.12M	Sell	15,363 -6,911	-31%	-$321K	0.01%	1758
2021 Q1	$825K	Buy	+22,274	New	+$1.12M	﹤0.01%	1754
2017 Q1	–	Sell	-29,988	Closed	-$4.02M	–	376
2016 Q4	$4.02M	Buy	29,988 +19,321	+181%	+$4.85M	0.03%	519
2016 Q3	$2.78M	Hold	10,667	–	–	0.02%	526
2016 Q2	$1.12M	Buy	+10,667	New	+$1.12M	0.01%	698

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGH

GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Marshall Wace's CLSD Position: Q3 2024 in Review

Marshall Wace sold out of Clearside Biomedical (CLSD) in Q3 2024, closing a stake of 4,141 shares — an estimated $80.8K sold.

Marshall Wace first reported a position in CLSD in Q2 2016 and held it in 11 quarters. The position peaked at $4.02M in Q4 2016. 48 funds tracked by Wall St. Rank hold CLSD as of Q3 2024.

Marshall Wace reported no remaining Clearside Biomedical position as of Q3 2024 after selling out during the quarter.
Marshall Wace sold 4,141 Clearside Biomedical shares in Q3 2024, an estimated $80.8K.
Marshall Wace first reported a position in Clearside Biomedical in Q2 2016 and held it in 11 quarters.
Marshall Wace's Clearside Biomedical position peaked at $4.02M in Q4 2016.
48 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.